Integer Holdings convertible notes become eligible, opening a Q4 dilution question

Integer is a medical-device contract manufacturer serving cardio and vascular, cardiac rhythm management, and neuromodulation markets, while also working through weaker adoption of several newer products and a strategic review of possible alternatives to remaining standalone.

The filing activates an existing note feature, not a new financing event. The 2.125% convertible notes became eligible for holder conversion during the quarter ending December 31, 2026 because the stock-price test was met for the quarter ended September 30. 〔0〕 This is a contractual, recurring mechanism rather than a change in Integer's operating plan or balance-sheet strategy.

The immediate business effect is only potential, not realized dilution. Holders now have the option to convert, but the filing does not say how much principal will be converted. Integer will pay cash up to the principal amount and can choose cash, shares, or a combination for any conversion value above principal. 〔1〕

This adds a near-term capital-structure decision while Integer is already under strategic scrutiny. If holders convert, the company could reduce debt but may need to use cash and/or issue shares; the filing provides no amount that would let investors size either outcome. The market already knew the notes could become convertible under the indenture, so the new information is that the price threshold was actually met—not a surprise change to the terms. Integer previously disclosed the same notes and their contractual conversion mechanics.

Bottom line: This is a routine confirmation that Integer's convertible notes are eligible for conversion in Q4, not a new operating signal. It matters mainly because actual conversions could alter cash usage, debt, and dilution, but the filing does not yet show whether that will happen or at what scale.**